Healthcare Industry News: ASTRO
News Release - November 13, 2009
Advances in Radiation Therapy Enable Doctors to Improve the Quality of Treatments for Patients With Head and Neck CancerNoted clinical experts detail recent developments at the annual ASTRO meeting in Chicago
PALO ALTO, Calif., Nov. 13 (Healthcare Sales & Marketing Network) -- Clinical studies suggest that advanced treatments like intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT) are enabling radiation oncologists to enhance post-treatment health-related quality of life for patients with head and neck cancer.
In an educational session for radiotherapy professionals, delivered by two noted experts during the annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago last week, Avraham Eisbruch, M.D., professor at the University of Michigan, discussed how careful implementation of IMRT in the treatment of head and neck cancer can achieve high tumor control rates while minimizing xerostomia, a dry mouth condition that occurs when salivary glands are damaged.
Citing a new report summarizing results from RTOG 0022, a multi-institutional study comparing IMRT with earlier forms of treatment for head and neck cancer, Dr. Eisbruch said that IMRT for head and neck cancer achieved important goals in reducing treatment toxicity, notably xerostomia, and in yielding a high tumor control rate of 90%.(1)
For patients enrolled in the study and treated with IMRT, only 55% experienced Grade 2 or worse xerostomia at six months after treatment, as compared with 84% of patients treated with earlier forms of radiotherapy -- a reduction of 35%. For the IMRT group, the percentage of patients with Grade 2 or worse xerostomia decreased steadily, to 25% at 12 months and 16% at 24 months. "This kind of improvement over time is not something we had been seeing with conventional forms of radiotherapy,(2)" said Dr. Eisbruch, who served as chair of RTOG 0022.
"Also, emerging data is suggesting that we can get improvements in broader aspects of post-treatment quality of life by using IMRT, beyond reducing xerostomia," Eisbruch said. "Several studies comparing IMRT with conventional radiotherapy found that the IMRT patients did better not just in terms of dry mouth, but also other quality of life dimensions, including swallowing and nutrition."(3)(4)(5)
According to Eisbruch, RTOG 0225, another multi-institutional study looked at IMRT with or without chemotherapy for head and neck cancer, and also reached positive conclusions. "That group reproduced the excellent results that individual treatment centers had been reporting, namely, a 90% loco-regional progression-free survival with minimal grade 3 and no grade 4 xerostomia."(6)
IMRT involves shaping radiotherapy treatment beams so that they deliver a dose pattern that matches the size and shape of a targeted tumor while minimizing exposure of surrounding healthy tissues and organs. This approach has been widely adopted by radiation oncologists for the treatment of diverse forms of cancer. Ongoing clinical studies are now maturing, allowing long term outcomes to be assessed and validating IMRT based on clinical data.
Improving IMRT Through Image-Guidance
Lei Dong, PhD, associate professor of medical physics at the MD Anderson Cancer Center in Houston, Texas, detailed how new image-guidance technologies further enhance the accuracy of IMRT treatments by enabling clinicians to correct for patient set-up uncertainties and anatomical changes over a course of treatment.
"Clinicians naturally want to take advantage of the more conformal dose distributions that IMRT makes possible by reducing the treatment margins around a tumor, to protect more healthy tissues," said Dr. Dong. "When we do that, it is important to ensure that the treatments are targeted very precisely, so the tumor receives the high dose treatments, and the dose to surrounding tissues and organs is kept as low as possible."
Dr. Dong discussed the issue of basing radiotherapy treatment plans on single CT scans taken during treatment simulation. "Internal motion can affect the accuracy of tumor definition if the CT scan is acquired while the patient is swallowing," he said, referencing a study he worked on with colleagues from M. D. Anderson Cancer Center.(7)
According to Dr. Dong, stereoscopic X-ray imaging and volumetric cone-beam CT imaging, two imaging techniques enabled by Varian's On-Board ImagerŪ kV imaging device, make it possible to fine-tune patient positioning just prior to each daily treatment. In addition, frequent imaging can alert clinicians to changes in a patient's anatomy over time, so that a new treatment plan can be developed part-way through a course of treatment whenever warranted--a process called adaptive radiotherapy.
"Preliminary studies have shown that combining IGRT and adaptive IMRT replanning can improve the overall quality of the treatment plan and, most importantly, reduce unnecessary doses to normal organs surrounding the tumor, such as the parotid glands and oral cavities," Dr. Dong said.(8) "Combining IGRT with IMRT creates a powerful tool for high precision radiation therapy."
ABOUT VARIAN MEDICAL SYSTEMS
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,100 people who are located at manufacturing sites in North America, China, and Europe and in its 79 sales and support offices around the world. For more information, visit http://www.varian.com/.
(1) Eisbruch A et al. Multi-Institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early-Stage Oropharyngeal Cancer (RTOG-022). Int. J. Radiation Oncology Biol. Phys., in press, doi:10.1016/j.ijrobp.2009.04.011.
(2) Logemann JA et al. Xerostomia: 12-month changes in saliva production and its relationship to perception and performance of swallow function, oral intake, and diet after chemoradiation. Head Neck. 2003 Jun;25(6):432-7.
(3) Pow EHN et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. Int. J. Radiation Oncology Biol. Phys., 2006;66:981-991.
(4) Graf P et al. Impact of Intensity-Modulated Radiotherapy on Health-Related Quality of Life for Head and Neck Cancer Patients: Matched-Pair Comparison with Conventional Radiotherapy. Int. J. Radiation Oncology Biol. Phys., 2007;67:1309-1317.
(5) Vergeer MR et al. Intensity-Modulated Radiotherapy Reduces Radiation-Induced Morbidity and Improves Health-Related Quality of Life: Results of a Nonrandomized Prospective Study Using a Standardized Follow-Up Program. Int. J. Radiation Oncology Biol. Phys., 2009;74:1-8
(6) Lee N et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009 Aug 1;27(22):3684-90.
(7) L. Dong, Y. P. Chen, M. E. Lindberg, A. S. Garden, D. I. Rosenthal, S. V. Sejpal, S. J. Shah, W. H. Morrison, K. K. Ang, D. L. Schwartz . Inter-fractional Movement of the Larynx and Oropharynx during Radiotherapy.
(8) D. Schwartz, K. Ang, G. Chronowski, D. I. Rosenthal, S. V. Sejpal, S. J. Shah, Y. Zhang, J. Garcia, A. Garden, L. Dong. Prospective Experience with CT-Guided Adaptive Radiotherapy for Head and Neck Cancer.
Source: Varian Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.